Edwards Lifesciences (EW) PT Lowered to $114 at Stifel, 'Buy' Kept
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St futures rise as AI stocks rally, crude prices fall
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Crypto stocks rise premarket as Bitcoin hits over seven-month high
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Streamflation drives 39% of Americans to cancel streaming in 6 months
- FortuneX and WT Realty announce $600M merger deal
Edwards Lifesciences Reports Third Quarter Results
October 25, 2016 4:15 PM EDTIRVINE, Calif., Oct. 25, 2016 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today reported financial results for the quarter ended September 30, 2016.
Third Quarter Highlights:
Sales grew 20.1% to $739.4 million; underlying1 sales were up 18.4% Global Transcatheter Heart Valve Therapy (THVT) sales grew 38.5% U.S. THVT sales were up 55.9% to $259.5 million GAAP EPS was $0.65, an increase of 20.4%; adjusted2 EPS grew 25.9% to $0.68 Reiterated... More